EA201891072A1 - Соединения для медицинских применений - Google Patents
Соединения для медицинских примененийInfo
- Publication number
- EA201891072A1 EA201891072A1 EA201891072A EA201891072A EA201891072A1 EA 201891072 A1 EA201891072 A1 EA 201891072A1 EA 201891072 A EA201891072 A EA 201891072A EA 201891072 A EA201891072 A EA 201891072A EA 201891072 A1 EA201891072 A1 EA 201891072A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- connections
- medical applications
- domain
- influenza
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000001450 anions Chemical group 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Согласно настоящему изобретению предложены соединения для применения в лечении и/или предупреждении гриппа. Соединение содержит первый домен и второй, причем первый домен содержит по меньшей мере одну якорную группу, которая связывается с поверхностью вирусов гриппа, и второй домен содержит по меньшей мере одну анионную группу. Первый и второй домены ковалентно связаны. Предложены также фармацевтически приемлемые соли, сольваты, пролекарства или стереоизомеры соединений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015904895A AU2015904895A0 (en) | 2015-11-20 | Compounds for medicinal applications | |
PCT/AU2016/051100 WO2017083914A1 (en) | 2015-11-20 | 2016-11-16 | Compounds for medicinal applications |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201891072A1 true EA201891072A1 (ru) | 2018-11-30 |
EA033921B1 EA033921B1 (ru) | 2019-12-10 |
EA033921B9 EA033921B9 (ru) | 2020-01-22 |
Family
ID=58717109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891072A EA033921B9 (ru) | 2015-11-20 | 2016-11-16 | Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа |
Country Status (19)
Country | Link |
---|---|
US (1) | US11007274B2 (ru) |
EP (1) | EP3377487B1 (ru) |
JP (1) | JP7034913B2 (ru) |
KR (1) | KR20180083402A (ru) |
CN (1) | CN108473483B (ru) |
AU (1) | AU2016356726C1 (ru) |
BR (1) | BR112018010027A2 (ru) |
CA (1) | CA3005774C (ru) |
EA (1) | EA033921B9 (ru) |
ES (1) | ES2911027T3 (ru) |
IL (1) | IL259425B (ru) |
MX (1) | MX2018005999A (ru) |
MY (1) | MY195168A (ru) |
PH (1) | PH12018501076A1 (ru) |
SG (1) | SG11201803962WA (ru) |
TW (1) | TWI742015B (ru) |
UA (1) | UA126654C2 (ru) |
WO (1) | WO2017083914A1 (ru) |
ZA (1) | ZA201803214B (ru) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
JP3691075B2 (ja) | 1996-11-14 | 2005-08-31 | バイオタ、サイアンティフィック、マネージメント、プロプライエタリ、リミテッド | 新規化合物およびその使用方法 |
AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
AUPR001000A0 (en) | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
AUPR879501A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
DE102004002132A1 (de) | 2004-01-15 | 2005-08-11 | Man Roland Druckmaschinen Ag | Einrichtung zur Erzeugung einer Beschichtung von Druckprodukten einer Druckmaschine |
JP5950390B2 (ja) | 2012-03-26 | 2016-07-13 | 国立大学法人 琉球大学 | 新規ミモシン誘導体 |
US10130714B2 (en) * | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
GB201313201D0 (en) * | 2013-07-24 | 2013-09-04 | Univ East Anglia | Virus Detection |
CN105085455A (zh) * | 2014-05-13 | 2015-11-25 | 中国科学院广州生物医药与健康研究院 | 唾液酸类似物或其药学上可接受的盐及其应用 |
-
2016
- 2016-11-16 MX MX2018005999A patent/MX2018005999A/es unknown
- 2016-11-16 AU AU2016356726A patent/AU2016356726C1/en active Active
- 2016-11-16 JP JP2018525746A patent/JP7034913B2/ja active Active
- 2016-11-16 UA UAA201806293A patent/UA126654C2/uk unknown
- 2016-11-16 CA CA3005774A patent/CA3005774C/en active Active
- 2016-11-16 EP EP16865298.0A patent/EP3377487B1/en active Active
- 2016-11-16 BR BR112018010027A patent/BR112018010027A2/pt active Search and Examination
- 2016-11-16 MY MYPI2018701859A patent/MY195168A/en unknown
- 2016-11-16 ES ES16865298T patent/ES2911027T3/es active Active
- 2016-11-16 SG SG11201803962WA patent/SG11201803962WA/en unknown
- 2016-11-16 CN CN201680075964.XA patent/CN108473483B/zh active Active
- 2016-11-16 EA EA201891072A patent/EA033921B9/ru not_active IP Right Cessation
- 2016-11-16 WO PCT/AU2016/051100 patent/WO2017083914A1/en active Application Filing
- 2016-11-16 KR KR1020187017047A patent/KR20180083402A/ko not_active Application Discontinuation
- 2016-11-18 TW TW105137966A patent/TWI742015B/zh active
-
2018
- 2018-05-15 ZA ZA2018/03214A patent/ZA201803214B/en unknown
- 2018-05-16 IL IL259425A patent/IL259425B/en unknown
- 2018-05-18 PH PH12018501076A patent/PH12018501076A1/en unknown
- 2018-05-18 US US15/984,029 patent/US11007274B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP7034913B2 (ja) | 2022-03-14 |
IL259425A (en) | 2018-07-31 |
PH12018501076A1 (en) | 2019-01-28 |
MX2018005999A (es) | 2018-11-22 |
EA033921B1 (ru) | 2019-12-10 |
CA3005774A1 (en) | 2017-05-26 |
KR20180083402A (ko) | 2018-07-20 |
NZ742593A (en) | 2023-08-25 |
UA126654C2 (uk) | 2023-01-11 |
JP2019502662A (ja) | 2019-01-31 |
AU2016356726A1 (en) | 2018-06-07 |
TWI742015B (zh) | 2021-10-11 |
US11007274B2 (en) | 2021-05-18 |
EA033921B9 (ru) | 2020-01-22 |
US20180264128A1 (en) | 2018-09-20 |
MY195168A (en) | 2023-01-11 |
AU2016356726B2 (en) | 2021-02-25 |
WO2017083914A1 (en) | 2017-05-26 |
CN108473483B (zh) | 2022-08-30 |
CA3005774C (en) | 2024-01-09 |
EP3377487B1 (en) | 2022-01-12 |
ZA201803214B (en) | 2019-07-31 |
CN108473483A (zh) | 2018-08-31 |
TW201726641A (zh) | 2017-08-01 |
SG11201803962WA (en) | 2018-06-28 |
BR112018010027A2 (pt) | 2018-11-21 |
EP3377487A4 (en) | 2019-07-17 |
IL259425B (en) | 2021-10-31 |
ES2911027T3 (es) | 2022-05-17 |
AU2016356726C1 (en) | 2021-12-09 |
EP3377487A1 (en) | 2018-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
EA201792214A1 (ru) | Соединения замещенного хиназолина | |
PH12017500207A1 (en) | Indoles for use in influenza virus infection | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
EA201591599A1 (ru) | Ингибиторы ido | |
EA201591823A1 (ru) | Ингибиторы ido | |
EA201690306A1 (ru) | Ингибиторы ido | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
EA201692470A1 (ru) | Фармацевтические комбинации | |
EA201790327A1 (ru) | Соединения замещенного пиперидина | |
EA201891644A1 (ru) | Антибактериальные соединения и их применение | |
EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
EA201792580A1 (ru) | Ингибиторы ido | |
EA201990095A1 (ru) | КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |